Anzeige
Erschienen in:
27.06.2018 | Correction
Correction to: Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry
Erschienen in: Heart and Vessels | Ausgabe 12/2018
Einloggen, um Zugang zu erhaltenExcerpt
In the original publication of the article, the data of Body mass index ≥ 25 (kg/m2)a is published incorrectly in Table 1. Since this is categorical variable, the data should have been expressed as a number (percentage), not as mean ± standard deviation. The corrected version of Table 1 is as below:
Table 1
Baseline characteristics and co-morbidities between the two groups in the entire cohort
|
Number
|
Entire cohort
|
||
|---|---|---|---|
|
Rhythm-control
|
Rate-control
|
P value
|
|
|
478
|
1279
|
||
|
Baseline characteristics
|
|||
|
Femalea
|
172 (36%)
|
560 (44%)
|
0.003
|
|
Age (years)a, mean ± SD
|
70.5 ± 10.8
|
74.3 ± 10.4
|
< 0.001
|
|
Age ≥ 75 years
|
183 (38%)
|
691 (54%)
|
< 0.001
|
|
Body mass index (kg/m2), mean ± SD
|
23.3 ± 3.6
|
23.0 ± 4.1
|
0.25
|
|
Body mass index ≥ 25 (kg/m2)a
|
104 (28%)
|
316 (28%)
|
0.96
|
|
Systolic blood pressure (mmHg), mean ± SD
|
125.3 ± 17.6
|
121.7 ± 18.4
|
< 0.001
|
|
Diastolic blood pressure (mmHg), mean ± SD
|
71.4 ± 11.1
|
69.2 ± 13.1
|
0.001
|
|
Pulse rate (beats/min)a, mean ± SD
|
75.0 ± 14.5
|
78.9 ± 16.3
|
< 0.001
|
|
Paroxysmal AFa
|
390 (82%)
|
428 (33%)
|
< 0.001
|
|
Previous cardiac device implantation
|
40 (8%)
|
100 (8%)
|
0.71
|
|
Estimated GFR (ml/min/m2), median, (25%, 75%)
|
50.5 (40.8, 61.1)
|
48.5 (36.8, 60.0)
|
0.17
|
|
Co-morbidities
|
|||
|
CHADS2 score, mean ± SD
|
1.53 ± 1.27
|
2.21 ± 1.28
|
< 0.001
|
|
CHA2DS2-VASc score, mean ± SD
|
2.71 ± 1.63
|
3.64 ± 1.62
|
< 0.001
|
|
History of stroke/TIAa
|
63 (13%)
|
229 (18%)
|
0.016
|
|
Heart failurea
|
48 (10%)
|
509 (40%)
|
< 0.001
|
|
Hypertensiona
|
278 (58%)
|
812 (63%)
|
0.040
|
|
Diabetes mellitusa
|
87 (18%)
|
306 (24%)
|
0.01
|
|
Coexistence of organic heart disease
|
50 (10%)
|
238 (19%)
|
< 0.001
|
|
Valvular heart diseasea
|
41 (9%)
|
326 (25%)
|
< 0.001
|
|
Coronary artery diseasea
|
50 (10%)
|
238 (19%)
|
< 0.001
|
|
Myocardial infarctiona
|
17 (4%)
|
106 (8%)
|
< 0.001
|
|
Cardiomyopathya
|
6 (1%)
|
56 (4%)
|
0.002
|
|
Left ventricular hypertrophya
|
5 (1%)
|
30 (2%)
|
0.064
|
|
Peripheral artery diseasea
|
14 (3%)
|
59 (5%)
|
0.10
|
|
Renal dysfunctiona
|
303 (72%)
|
915 (75%)
|
0.38
|
|
Chronic obstructive pulmonary diseasea
|
20 (4%)
|
68 (5%)
|
0.33
|
|
Anemiaa
|
42 (10%)
|
211 (17%)
|
< 0.001
|
|
History of major bleeding
|
10 (2%)
|
49 (4%)
|
0.072
|
|
Prescription at baseline
|
|||
|
Oral anticoagulant
|
226 (47%)
|
858 (67%)
|
< 0.001
|
|
Warfarin
|
188 (39%)
|
771 (60%)
|
< 0.001
|
|
Dabigatran
|
25 (5%)
|
42 (3%)
|
0.058
|
|
Rivaroxaban
|
12 (3%)
|
26 (2%)
|
0.54
|
|
Apixaban
|
1 (0.2%)
|
19 (1%)
|
0.025
|
|
Anti-platelet drug
|
111 (23%)
|
425 (33%)
|
< 0.001
|
|
Diureticsa
|
64 (13%)
|
546 (43%)
|
< 0.001
|
|
Loop diuretics
|
37 (8%)
|
462 (36%)
|
< 0.001
|
|
Thiazide diuretics
|
21 (4%)
|
49 (4%)
|
0.60
|
|
Spironolactone
|
14 (3%)
|
222 (17%)
|
< 0.001
|
|
Renin–angiotensin system inhibitorsa
|
187 (39%)
|
652 (51%)
|
< 0.001
|
|
Echocardiography
|
|||
|
LV ejection fraction (%)a, mean ± SD
|
66.9 ± 9.2
|
60.4 ± 13.0
|
< 0.001
|
|
LV ejection fraction ≤ 50%
|
6 (2%)
|
103 (8%)
|
< 0.001
|
|
LA dimension (mm)a, mean ± SD
|
40.2 ± 6.0
|
46.1 ± 8.3
|
< 0.001
|